Sign in

    Nevin Varghese

    Research Analyst at RBC Capital Markets

    Nevin Varghese is an Associate at RBC Capital Markets, specializing as an equity research analyst with a focus on the biotechnology and healthcare sectors. He has participated in coverage of companies such as Galapagos NV and has contributed to research discussions on financial results and pipeline developments for leading biotech firms. Varghese began his career after earning a doctorate from Columbia University and has been with RBC Capital Markets since completing his advanced academic training. He holds professional credentials relevant to equity research analysis and is noted for his strong analytical background stemming from his doctoral studies.

    Nevin Varghese's questions to ITCI leadership

    Nevin Varghese's questions to ITCI leadership • Q3 2024

    Question

    Asked about the expected launch trajectory for CAPLYTA in MDD, its comparison to Vraylar's launch, and the potential competitive impact of KarXT in schizophrenia.

    Answer

    A rapid uptake in MDD is expected, similar to or better than analogs like Vraylar, due to CAPLYTA's strong clinical profile. They do not anticipate a significant impact from KarXT, as CAPLYTA's long-term growth is in mood disorders where KarXT doesn't compete, and CAPLYTA's tolerability profile is a key advantage in the schizophrenia switching market.

    Ask Fintool Equity Research AI